Atamyo Therapeutics

Stephane Degove, CEO

Oct. 10 | 5:15pm | Rentschler ATMP Ballroom 

Paris, France


Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for muscular dystrophies and cardiomyopathies. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo’s most advanced programs address different forms of limb-girdle muscular dystrophies (LGMD), with two clinical-stage program targeting LGMD-R9 and LGMD-R5. Other programs target LGMD-R1 and Dilated Cardiomyopathies.

By using this website you agree to accept our Privacy Policy and Terms & Conditions